David Budd, chief executive of Genedrive PLC (LON:GDR) and Bill Newman, Professor of Translational Genomic Medicine at the University of Manchester discuss with Proactive Investors the grant awarded to Genedrive for a point-of-care pharmacogenetic test to avoid antibiotic-related hearing loss in newborn children.
The project's expected to commence immediately, with an expected development phase of one year followed by a trial implementation phase in selected NHS hospitals in year two.
Original Article: Genedrive receives NHS grant to develop and implement point-of-care test